Tesamorelin: Mechanism, Research, and Regulatory Status

Tesamorelin stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop via somatostatin. Direct GH injection delivers a constant supraphysiological bolus that bypasses regulatory mechanisms. This means tesamorelin maintains more physiological IGF-1 levels and a natural pulsatile GH profile, which is associated with fewer side effects (edema, insulin resistance, acromegalic changes) than direct GH use at equivalent doses.

Egrifta® (clinical formulation) is reconstituted with the supplied sterile water at 1 mg/mL. For lyophilized research-grade tesamorelin, reconstitute with bacteriostatic water: inject diluent slowly down the vial wall, swirl gently (do not shake), and allow 3–5 minutes for full dissolution. Typical research concentration: 1–2 mg/mL. Store reconstituted solution at 2–8°C; use within 21–28 days.

Lyophilized powder: −20°C in a sealed, opaque container away from moisture. The trans-3-hexenoic acid modification is stable but should be protected from oxidative conditions. Allow to warm to room temperature before opening. After reconstitution, store at 2–8°C; do not freeze the reconstituted solution.

Yes. GH secretion declines ~14% per decade after age 30 (somatopause). Research has evaluated tesamorelin in older adults to restore GH pulsatility, preserve lean mass, reduce visceral fat, and improve cognitive function. A Phase 2 trial (Friedman et al., Neurology 2019) in adults 60+ with mild cognitive impairment showed improved cognition and reduced brain amyloid, suggesting potential neuroprotective utility.

In clinical trials, tesamorelin 2 mg/day raised IGF-1 from below-normal to within the physiological reference range for young adults (~150–350 ng/mL) in HIV lipodystrophy patients. Mean IGF-1 SD score increased from −1.0 to +0.2 at 26 weeks. This normalization, rather than supraphysiological elevation, is considered a key safety advantage. Monitoring IGF-1 levels is standard practice in tesamorelin research to avoid excessive elevation.

Yes. WADA classifies all GHRH analogs, including tesamorelin, under the S2 Prohibited List (Peptide Hormones, Growth Factors, Related Substances). Athletes subject to anti-doping rules may not use tesamorelin, even with a therapeutic use exemption, outside of very narrow medical necessity criteria. This classification applies even though tesamorelin is FDA-approved for lipodystrophy.

Tesamorelin (GHRH analog) and GH secretagogues like ipamorelin act on synergistic pathways. GHRH amplifies GH pulse amplitude, while GH secretagogues (acting via the ghrelin receptor GHS-R1a) increase pulse frequency. Combination in preclinical models produces additive GH release. Researchers studying GH axis optimization often evaluate this combination, though clinical safety data for the combination is limited.

In Phase 3 HIV lipodystrophy trials, tesamorelin produced: −26 mg/dL triglycerides, reduction in non-HDL cholesterol, slight improvement in HDL, and a modest reduction in carotid intima-media thickness (IMT), a surrogate for cardiovascular risk. No significant change in total cholesterol or fasting glucose was observed at standard doses, and insulin resistance was not meaningfully worsened.